| Identification | Back Directory | [Name]
PI3K inhibitor | [CAS]
1202884-94-3 | [Synonyms]
CAY10626
PI3K inhibitor
Antitumor Drug
N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-yl-7-(2,2,2-trifluoroethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]phenyl}carbamoyl)amino]benzamide
BenzaMide, N-[2-(diMethylaMino)ethyl]-N-Methyl-4-[[[[4-[4-(4-Morpholinyl)-7-(2,2,2-trifluoroethyl)-7H-pyrrolo[2,3-d]pyriMidin-2-yl]phenyl]aMino]carbonyl]aMino]- | [Molecular Formula]
C31H35F3N8O3 | [MDL Number]
MFCD18251469 | [MOL File]
1202884-94-3.mol | [Molecular Weight]
624.66 |
| Chemical Properties | Back Directory | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 15 mg/ml; DMSO: 15 mg/ml; DMSO:PBS (pH 7.2) (1:10): 0.1 mg/ml | [form ]
A crystalline solid | [pka]
13.74±0.70(Predicted) |
| Hazard Information | Back Directory | [Description]
The PI3Kinases are important downstream effectors of KRAS signaling. In preclinical studies, buparlisib (BKM120), a PI3K inhibitor, when combined with MEK
inhibitor (PD1056309) led to significant synergistic activity in KRAS mutant
NSCLC cell lines. | [Definition]
ChEBI: CAY10626 is a member of ureas. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Resenbio
|
| Tel: |
029-86354885 |
| Website: |
www.xarxbio.com |
|